Merck & Co Inc (LTS:0QAH)
$ 131.3 0 (0%) Market Cap: 249.37 Bil Enterprise Value: 272.91 Bil PE Ratio: 20.67 PB Ratio: 5.61 GF Score: 81/100

Merck & Co Inc Cardiovascular Event Transcript

Apr 05, 2022 / 02:00PM GMT
Release Date Price: $84.78 (+1.39%)
Operator

Good morning. My name is Grace Lacker, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Merck & Co., Inc.'s Cardiovascular Investor Event. (Operator Instructions) I would now like to turn the call over to Peter Dannenbaum, Vice President of Investor Relations. Please go ahead.

Peter Dannenbaum
Merck & Co., Inc. - VP of IR

Thank you, Grace, and good morning, everyone. Welcome to Merck's Cardiovascular Investor Event. We are excited to have this opportunity to speak to you today about our broad and growing cardiovascular portfolio. During today's call, a slide presentation will accompany our speakers' prepared remarks. This presentation is posted to the Investor Relations section of Merck's website.

Speaking on today's call will be Eliav Barr, Senior Vice President, Head of Global Clinical Development and Chief Medical Officer; Arpa Garay, Chief Marketing Officer, Human Health; Joerg Koglin, Vice President, Global Clinical Development, Cardiovascular and Respiratory; Dean Li, President, Merck

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot